Please login to the form below
Gilead makes senior changes
Expanded roles for Andrew Cheng and Taiyin Yang
Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.
Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.
Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.
Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.
“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”
Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.
Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen reports positive results for Otezla in psoriatic arthritis
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by EC for older adults
- The 17th World Congress on Controversies in Neurology
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
No results were found
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
